New diabetes drug approved in USA

Novo Nordisk has received US Food and Drug Administration (FDA) approval for Fiasp (fast-acting insulin aspart) for the treatment of adults with diabetes.

Fiasp is a new fast-acting mealtime insulin that has already been approved by regulators in Europe and Canada, and is designed to work faster than earlier treatments such as Eli Lilly’s Humalog (insulin lispro) and Novo Nordisk's own NovoLog/NovoRapid.